75 results about "Prolonged action" patented technology

A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin solid dispersion contains povidone K30, soybean lecithin and acrylic resin IV, and the mass ratio between silymarin and other medical accessories in silymarin solid dispersion is silymarin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silymarin disclosed in this invention is 2.3 times longer while the mean residence time (MRT) of which is 9.94 times longer; when tested in vivo in Beagle dogs, this new formulation of silymarin presents a smoother concentration-time curve and reaches a continuous release for 72 hours. This invention discloses its preparation method.

The present invention relates to pharmaceutical compositions comprising a peptide that stimulates the release of gonadotropins and sexual steroids. More specifically, the present invention provides pharmaceutical compositions comprising kisspeptin, preferably in the kp-10 form, or derivatives thereof, for use in ovulation cycle inducing and / or infertility treatment programs. The formulations according to the present invention belong to two main groups: injectable solutions and implantable formulations. The injectable solutions according to the present invention can be divided into immediate release solutions and prolonged action solutions. The implantable formulations according to the present invention can be prepared using an RTV silicone elastomer, a rapid vulcanization silicone elastomer or a rapid vulcanization silicone elastomer with a release modulator.

The invention relates to a sustained-release preparation of compound metformin hydrochloride rosiglitazone and a preparation method thereof; wherein, rosiglitazone and metformin hydrochloride have slow releasing characteristic in an in-vitro dissolution test, the rosiglitazone is released by 10-30 percent for a first hour, and is released by 60-80 percent for a fourth hour, and is released by morethan 80 percent for an eighth hour; the metformin hydrochloride is released by 15-40 percent for a first hour, is released by 50-70 percent for a fourth hour, and is released by more than 75 percentfor an eighth hour. The formula is mild and has prolonged action of glucose reduction, so as to avoid adverse reaction such as hypoglycemia and gastrointestine malaise, reduce taking times (one or twotimes each day), and improve compliance of a patient. The invention discloses the in-vitro drug-releasing characteristic of the sustained-release preparation and the preparation method thereof.

Duloxetine hydrochloride sustained-release medicine is composed of duloxetine hydrochloride and acceptable excipients in oral medicine, wherein duloxetine hydrochloride is 15% to 65% of the total weight of the drug, and the excipients are At least include polymer matrix slow-release materials, release rate regulating components and enteric coating materials, and polymer matrix slow-release materials are 1% to 80%, release rate regulating components are 0.1% to 50%, enteric coating materials The coating material is 1.5% to 10%. The drug has a skeleton-type slow-release function of intestinal erosion, quick onset, strong drug effect, and prolonged action time, which can significantly reduce the adverse reactions of instantaneous drug release after taking the drug, make the blood drug concentration and drug effect more stable and durable, and enhance Patient compliance and clinical treatment outcomes.

The invention relates to a kind of lubricating and anti-friction multiphase material as well as its preparing method, especially the new type material that uses the heat proof thermoplastic medlin as the frame material being filled with grease. The invention adopts heat proof thermoplastic medlin as the frame and high drop point grease as the lubricant. The grease is put into the pore of the material by high temperature vacuum permeating method to form the lubricating and anti-friction multiphase material. The grease is enveloped inside to prevent its expire by oxidation; during the rubbing process, the grease can form steady lubricating membrane by the discrepancy of thermal expansion quotient and centrifugation; besides, the constant renewal of the rubbing surface ensured the prolonged action of the grease to fulfill the working conditions of high temperature and high speed.

The invention discloses graphene nano-silver lidocaine slow-release antibacterial gel. The preparation method comprises the following steps: performing supersonic decomposing on single-layer grapheneoxide in deionized water so as to obtain an aqueous solution of nano graphene oxide; adding silver nitrate and a reducing agent into the aqueous solution of nano graphene oxide so as to obtain nano-silver graphene oxide Ag-nGO; mixing the nano-silver graphene oxide and lidocaine to obtain an Ag-nGO-lido mixture; and dissolving Carbomer 940, PEG400 and glycerin into deionized water, enabling the Carbomer 940 to be fully dispersed at a normal temperature, dissolving the Ag-nGO-lido into the dispersed solution after dispersing, adding sodium hydroxide and potassium sorbate to be dissolved, supplementing deionized water, and fully mixing, thereby obtaining the product. The graphene nano-silver lidocaine slow-release antibacterial gel disclosed by the invention has the beneficial effects that the lidocaine is adsorbed onto the surface of a nano-carrier, is slowly released and has effects of obviously prolonging action time of the lidocaine and enhancing transdermal effects of drugs; a graphene composite nano-silver material serves as a carrier, the graphene and silver ions have antibacterial effects, particularly the silver ions have excellent antibacterial abilities and do not have drug tolerance, and risk of infection caused by long-term retention catheterization can be reduced.

The invention discloses abscisic acid-embedded chitosan nanoparticles and a preparation method thereof. The abscisic acid-embedded chitosan nanoparticles are nanoparticles formed by wrapping aqueous solution of abscisic acid by an embedding material which is formed by dilute solution of acetic acid of chitosan and a crosslinking agent. The preparation method comprises the following steps of: adding the chitosan into the dilute solution of acetic acid to be dissolved, and then adding solution of sodium hydroxide to adjust the pH value to obtain dilute solution of acetic acid of the chitosan; preparing abscisic acid into aqueous solution; preparing the crosslinking agent into aqueous solution; adding the solution of dilute acetic acid of the chitosan into the aqueous solution of abscisic acid, and then adding the aqueous solution of crosslinking agent drop by drop; and fully mixing uniformly to obtain the abscisic acid-embedded chitosan nanoparticles. The method is simple and easy, and has high embedding rate; the obtained embedding nanoparticles have no adhesion, good glomeration and round surface; after the embedding, the abscisic acid can be protected from external interference, and the stability of the abscisic acid can be improved; the abscisic acid is steadily and slowly released, which prolongs action time and strengthens induced resistance effect; and the chitosan serving as a wall material has disease-resistant and induced resistance effects.

Cyclic peptide agonists toward human galanin receptor 2 (GalR2) and galanin receptor 3 (GalR3) based on hidden conformation of spexin solution structure for GalR2 and GalR3-related and spexin-deficient disorders are designed and synthesized. LH101, LH102, and LH101 (Ac) are potent spexin analogs with prolonged action, which can be used in the treatment of GalR2 and GalR3-related diseases and spexin-deficient disorders, such as obesity.